ABSTRACT The CRISPR-Cas system, especially the type II CRISPR-Cas9 system from Streptococcuspyogenes, has rapidly emerged as a popular genome editing tool. The development of Cas9 derivatives further expanded the toolbox of CRISPRCas9 based genome editing kit. However, therapeutic translation of the CRISPR-Cas9 system in vivo is severely impeded by the absence of an appropriate delivery carrier. The complexity and high molecular weight of the CRISPR-Cas9 system, together with the physiological barriers for nucleus targeted cargo transportation have made it a huge challenge for in vivo therapeutic CRISPR-Cas9 delivery. Currently, the main stream carriers for systemic delivery of CRISPR-Cas9 are viral based, such as adeno-associated virus. However, the safety concerns surrounding viral vectors call for the development of non-viral nanocarriers. In this review, we survey the recent advances in the development of non-viral delivery systems for CRISPR-Cas9. Challenges and future directions in this field are also discussed.
INTRODUCTION
The promise of treating disease from the genetic roots made gene therapy an actively pursued modality by both scientists and the general public [1] [2] [3] [4] . The therapeutic effect is achieved by applying genetic tools to precisely manipulate genetic materials within targeted cells, including disruption, insertion, deletion, mutation and replacement [5] . Ongoing clinical trials of gene therapy shed light on treating serious genetic diseases associated with different physiological systems, such as the immune, nervous or blood circulation systems [6] . The type II CRISPR-Cas (clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR associated protein) system has rapidly emerged as a facile genetic engineering tool for targeted interrogation of almost any gene in any organism [7, 8] . Early investigations coined the popular CRISPR-Cas9 system from Streptococcus pyogenes as a site-specific endonuclease that could bind with a single guiding RNA (sgRNA) to recognize specific DNA sequences for cleavage [9] . Cleavage of the targeted DNA loci in the genome introduces double stranded DNA breaks, which could be repaired by the cells through different pathways. Typically, DNA repair of the cleavage introduces insertions or deletions (indels) through the error-prone non-homologous end joining pathway (NHEJ), a mechanism usually adopted for targeted gene disruptions [10] . In the presence of a pre-designed donor DNA, precise genome editing could occur incorporating sequence from the donor DNA into the genome by homologous recombination [11] . The site-specific nuclease activity makes CRISPR-Cas9 a powerful tool in achieving permanent changes to the genomes. Further development of Cas9 by disabling its enzymatic activities generates a "dead" version of Cas9, termed as dCas9, that could be fused with different functional protein domains to achieve transcriptional control, epigenetic regulation or imaging [12] .
Delivered by traditional gene transfection methods, such as mechanical deformation of cell membrane [13] , electroporation [14] , lipofection [15] , microinjection [16] or viral based transfection [17] , CRISPR-Cas9 system were widely adopted in ex vivo editing of germline cells from different species for the purpose of curing genetic disease in the off-springs of genetically diseased rats [18] , reprogramming mice [19, 20] or monkey zygotes [21] to create animal models for scientific study, or even the controversial human germline cells for therapeutic studies [22, 23] . However, these proof-of-principle studies may not be directly translated into therapeutic applications [24] . Recent therapeutic application of CRISPR is an indirect approach that focused on the ex vivo editing of immune cells for cancer immune therapy, like chimeric antigen receptors T (CAR-T) cells [25] . However, to realize the prospect of curing hereditary genetic disease in animals after birth, the development of a suitable delivery method is the number one challenge [26, 27] .
NONVIRAL CARRIER-MEDIATED CRISPR DELIVERY
Many obstacles exist for delivering the CRISPR-Cas9 system: 1) Cas9 is a large protein (~160 kDa) with genetic sequence over 4000 base pairs (bp), making it an overwhelmingly huge load even for the well-established adenoassociated virus (AAV) based carriers [28] ; 2) CRISPRCas9 is multicomponent system composed of Cas9 protein, sgRNA and an optional donor DNA, which makes it desirable to create carriers capable of delivering the three different types of biomolecules simultaneously; 3) CRISPR-Cas9 takes effect in the nuclei of cells, and to reach this destination, multiple physiological barriers need to be overcome, such as avoiding proteases and nucleases in blood circulation, extravasation into desired tissue, penetrating the plasma membrane of targeted cells, escaping the endolysosome entrapment after endocytosis, and infiltrating the nuclear membrane [29] .
In contrast to the facile adaptation of almost all types of viral carriers to fit the CRISPR-Cas9 system [30] , it has been a tough task to design efficient non-viral nanocarriers for systemic administration. In the first demonstration of CRISPR based therapeutic genome editing in adult animal, Anderson and coworkers [11] directly administered a plasmid encoding the Cas9 and sgRNA with a single-stranded DNA (ssDNA) donor to correct a single point mutation associated disease (hereditary tyrosinemia type I, HTI) in mouse liver by hydrodynamic injection via the tail vein. A 0.4% initial gene correction efficacy was achieved by this method. Recently, a core-shell structured polymeric nanocarrier has been reported to deliver the all-in-one plasmid for gene disruption in cancer therapy [31] . The fluorinated polymer core and hyaluronic acid shell based formulation induced 44% gene disruption in vitro and reduced targeted gene expression in vivo after intraperitoneal drug administration.
An alternative to the delivery of nucleic acid based CRISPR-Cas9 system is to deliver the CRISPR-Cas9 components as purified protein and RNA. Direct delivery of the ribonucleoprotein would save the time for cells to express them from the all-in-one plasmid, facilitating the onset of the gene editing process [32] . The absence of a plasmid DNA when delivering the ribonucleoprotein would obviate the concern of integrating plasmid into the genome of targeted cells [33] . It has been demonstrated that the Cas9/sgRNA ribonucleoprotein delivery strategy enabled better control of Cas9/sgRNA dosage and reduced the chance of off-target cleavage when compared with the plasmid delivery strategy [34] . Kim and coworkers [35] applied a cell penetrating peptide with 9 Arginine (9R) to deliver purified Cas9 and sgRNA (Fig. 1a) . Cas9 was conjugated to 9R via a redox cleavable linker while sgRNA was complexed with 9R through electrostatic interaction. After co-administration of these two nanoparticles, 8.7% gene disruption was achieved in a HEK293T cell line. Besides the highly positively charged peptide, cationic lipids were also applied for Cas9/sgRNA ribonucleoprotein delivery [32, 36] . The Cas9/sgRNA ribonucleoprotein has a net negative charge, making it easy to form stable nano-complex with the cationic lipids. A synthetic redox responsive lipid nanocarrier showed 70% gene disruption in a reporter cell line [36] , and a commercially available lipid based carrier (Fig. 1b) has generated 20% gene modifications in an in vivo hair cell model after local injection [32] .
Our group has recently developed a synthetic DNA nanoclew (NC) based carrier for delivering the CRISPR-Cas9 system in vitro and in vivo for gene disruption [37] . As shown in Fig. 1c , the DNA NC containing sequence complementary to the targeting region of sgRNA was prepared by a facile DNA synthesis technique named rolling circle amplification [38] . Purified Cas9 protein and sgRNA formed a ribonucleoprotein that could bind to the DNA NC via specific base-pairing between sgRNA and DNA NC. After loading Cas9/sgRNA into the DNA NC, a positively charged polymer polyethylenimine (PEI) was coated onto the nanoparticle for facilitated endosome escape. The final formulation containing the DNA NC core, Cas9/sgRNA cargo and a PEI coating formed uniformly sized nanoparticles with a mean hydrodynamic size of 56 nm, which was an appropriate size for efficient drug delivery. A model bone osteosarcoma cell line expressing a destabilized version of EGFP (U2OS.EGFP) was chosen as reporter cell line [39] . Optimized DNA NC with partial complementarity to the sgRNA showed the highest Cas9/ sgRNA delivery efficacy, disrupting EGFP gene in 37% of the treated population in vitro. We also investigated the in vivo gene editing efficacy of Cas9/sgRNA delivered by the DNA NC based carrier. In a xenograft tumor model built with the U2OS.EGFP cell line, 25% of the U2OS.EGFP cells in the locally treated region lost EGFP expression after 10 days of the treatment while cells in the untreated group all remained EGFP positive.
Besides using non-viral carriers only, combined non-viral and viral carriers were also demonstrated for enhanced genome editing efficacy. With the HTI as model disease, modified mRNA of Cas9 was encapsulated into a C12-200 based lipid nanoparticle, while the sgRNA and donor DNA was packaged into AAV (Fig. 1d) . Single administration of the lipid complexed mRNA could lead to 77% gene disruption in a reporter cell line, while the combined viral and non-viral therapy induced 6% gene correction in the targeted hepatocytes after intravenously injection [40] .
CONCLUSIONS
In summary, the task of delivering the huge and complex CRISPR system for therapeutic applications in vivo has remained challenging, and the race to develop an efficient and biocompatible non-viral nanocarrier has just begun. Currently reported non-viral nanocarriers share the common feature of adopting cationic materials. However, these cationic components could interfere with serum proteins if administered intravenously, which might compromise their therapeutic efficacy as well as biocompatibility. To develop a better nanocarrier, more biocompatible biomaterials that could efficiently package the multicomponent CRISPR into one nanocarrier and escape the endosome entrapment for efficient nuclear delivery are needed [41, 42] .
